Drug intelligence / Profile preview

Liqin Zhike Formula

Development stage: Unknown
Lead developer: Second Affiliated Hospital of Zhejiang University School of Medicine
Modality: Small Molecules
Administration: Oral

Overview

Liqin Zhike Formula is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University. It is primarily indicated for the treatment of cough variant asthma (CVA), a phenotype of asthma characterized by a chronic non-productive cough and airway hyperresponsiveness. The formula is typically administered orally as an adjunct to standard-of-care inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). It is designed to enhance clinical efficacy, reduce cough frequency, and improve the long-term prognosis of patients by targeting the underlying inflammatory processes associated with CVA.

Other names: Liqin Zhike

Beyond the preview

Go deeper on Liqin Zhike Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liqin Zhike Formula.

Explore the full profile